ETON

Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals Inc (ETON) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C
Factor Score 2.5 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 206.8
Rev Growth YoY 40.4%
Gross Margin 59.7%
Price Return 3M 52.0%
Price Return 12M 224.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 14.4
ROE -5.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C (2.5) B (3.3) B- (3.0) C (2.4) C- (1.9) C+ (2.6)
2026-08-04 C (2.5) B (3.3) B- (3.0) C (2.4) C- (1.9) C+ (2.6)
2026-08-03 C (2.5) B- (3.0) B- (3.1) C (2.4) C- (2.0) C+ (2.6)
2026-08-02 C (2.5) B- (3.0) B- (3.0) C (2.4) C- (1.9) C+ (2.6)
2026-07-29 C+ (2.5) A+ (5.0) B (3.4) A+ (4.9) D+ (1.5) B (3.5)
Page 1 of 2